Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Jun 2023
MoonLake Immunotherapeutics
Top line results from Phase 2 trial of Sonelokimab (MIRA)
Hidradenitis Suppurativa
May 2023
PTC Therapeutics Inc.
Results from phase III trial of Sepiapterin (PTC923) (APHENITY)
Phenylketonuria
Mid 2023
COMPASS Pathways plc
Preliminary data from Phase II trial of CTX-009
Metastatic Colorectal Cancer
Mid 2023
Bellerophon Therapeutics LLC
Top-line data readout from INOpulse REBUILD phase III trial
Fibrotic interstitial lung disease
Mid 2023
PROKIDNEY CORP.
Initial interim data from phase II trial of REACT (REGEN-007)
Type 1 or 2 diabetes and chronic kidney disease
Mid 2023
Scholar Rock Holding Corp
36-month extension data from phase II trial of Apitegromab (TOPAZ)
Spinal muscular atrophy (SMA) type 2 and 3
Mid 2023
Travere Therapeutics Inc
Additional data from phase I/II study of Pegtibatinase (COMPOSE)
Classical homocystinuria
Mid 2023
Vaxart, Inc.
Topline data from Phase 2 dose-ranging study of bivalent norovirus oral vaccine candidate
Norovirus
Mid 2023
UroGen Pharma Ltd.
Topline results from pivotal phase 3 study of UGN-102 (ENVISION)
Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Mid 2023
UroGen Pharma Ltd.
Topline data from phase 3 trial of UGN-102 (ATLAS)
Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Mid 2023
Alaunos Therapeutics Inc.
Interim data from phase I/2 trial of TCR-T cells
Non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers
Mid 2023
NextCure Inc
Phase 1b update from Phase 1b/2 clinical trial of NC410 in combination with Keytruda
Immune checkpoint refractory or naïve solid tumors
Mid 2023
Homology Medicines, Inc.
Initial clinical data from phase I trial of HMI-103 (pheEDIT)
Phenylketonuria
Mid 2023
Lipocine Inc
Topline results from Phase 2 proof-of-concept study of LPCN 1148
Management of decompensated cirrhosis of various etiologies
Mid 2023
Immuneering Corp
Initial Phase 1 PK and safety data from Phase 1/2a clinical trial of IMM-1-104
Advanced solid tumors with any RAS mutation
Mid 2023
Acurx Pharmaceuticals, Inc
Interim review of clinical data from Phase 2b trial of oral ibezapolstat
C. difficile infection
Mid 2023
Surrozen, Inc.
Data from phase Ia trial of SZN-1326 in healthy volunteers
Ulcerative colitis
Mid 2023
FibroGen Inc.
Topline data from the ZEPHYRUS-1 Phase 3 study of Pamrevlumab
Idiopathic Pulmonary Fibrosis
Mid 2023
FibroGen Inc.
Topline data from the ZEPHYRUS-2 Phase 3 study of Pamrevlumab
Idiopathic Pulmonary Fibrosis (IPF)
Mid 2023
Mersana Therapeutics, Inc.
Topline results from phase I/II UPLIFT trial of Upifitamab Rilsodotin (UpRi)
Platinum Resistant Ovarian Cancer
Mid 2023
Aravive, Inc.
Topline data from phase III trial of Batiraxcept
Platinum resistant ovarian cancer
Mid 2023
Aravive, Inc.
Additional data from phase Ib portion of Batiraxcept
Clear cell renal cancer
Mid 2023
Aravive, Inc.
Preliminary data from phase II portion of Batiraxcept
Clear cell renal cancer
Mid 2023
FibroGen Inc.
Topline data from the China Phase 3 study of Roxadustat
Chemotherapy-Induced Anemia (CIA)
Mid 2023
Shattuck Labs, Inc
Data from Phase 1 dose-escalation clinical trial of SL-172154
Platinum-Resistant Ovarian Cancer